Metraipolis › archive › dc_113ee787d971
Engineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations — Europe PMC PMID:41059158
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41059158
- DOI
- 10.1039/d5me00106d
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T21:10:29.506Z
- SHA-256 of the archived text
eec2253c72aedb978ffccf00df7bed238e4e9e5384d777dfe49aca7f9b0f67fa- Stable URL of this page
https://metraipolis.com/documento/dc_113ee787d971
How to cite
Engineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations — Europe PMC PMID:41059158 — Europe PMC (en), https://europepmc.org/article/MED/41059158 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_113ee787d971 (Metraipolis archive dc_113ee787d971, sha256 eec2253c72aedb978ffccf00df7bed238e4e9e5384d777dfe49aca7f9b0f67fa)
BibTeX
@misc{dc113ee787d971,
title = {Engineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations — Europe PMC PMID:41059158},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41059158},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_113ee787d971; sha256 eec2253c72aedb978ffccf00df7bed238e4e9e5384d777dfe49aca7f9b0f67fa},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41059158. Agents can read the archived copy with the MCP tool read_document.